These transgenic mice express the human MCL1 under the direction of the human endogenous promoter. Mice exhibit enlarged spleens, increased total splenocyte number, lymph node enlargement and a high probability of developing lymphomas. This transgenic mouse strain may be useful in studies related to tumorigenesis and inhibition of tumorigenesis in the presence of a viability-promoting BCL2 family member.
Ruth W. Craig, Dartmouth Medical School
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
These transgenic mice express the human MCL1 under the direction of the human MCL1 promoter. Expression of the human MCL1 protein was immunodetectable. Mice hemizygous for the transgene exhibited human MCL1 in bone marrow, lymph node, thymus and spleen (both B- and T-cell populations). Low levels of transgene expression was found in kidney, small intestine, uterus, lung and liver. The majority of the transgenic mice had enlarged spleens, with an increased total splenocyte number (both B- and T-cell). Transgenic mice displayed an increase of myeloid cells relative to lymphoid cells in bone marrow, and an enhanced viability of hematopoietic and lymphoid cells (B, T and myeloid) at immature and mature stages of development. In transgenic mice from 6 to 11 months of age, 27% displayed lymph node enlargement. Transgenic mice had an 88% probability of developing pathologic lymph node disease, and a 60% probability of developing disseminated disease from 6 months to 2 years of age. The lymphomas in the transgenic mice were predominantly of clonal B-cell origin and displayed a variety of histological subtypes including follicular lymphoma and diffuse large-cell lymphoma. This transgenic mouse strain represents a model that may be useful in studies related to tumorigenesis and inhibition of tumorigenesis in the presence of a viability-promoting BCL2 family member.
A transgenic construct containing the entire human MCL1 gene, including the endogenous MCL1 promoter, was microinjected into B6;SJLF1 fertilized oocytes. Founder animals were bred to C57BL/6J mice.
Expressed Gene | MCL1, MCL1, BCL2 family apoptosis regulator, human |
---|---|
Site of Expression |
Allele Name | transgene insertion 8, Ruth W Craig |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | |
Gene Symbol and Name | Tg(MCL1)8Caig, transgene insertion 8, Ruth W Craig |
Gene Synonym(s) | |
Promoter | MCL1, MCL1, BCL2 family apoptosis regulator, human |
Expressed Gene | MCL1, MCL1, BCL2 family apoptosis regulator, human |
Strain of Origin | (C57BL/6 x SJL)F1 |
Chromosome | UN |
Molecular Note | The transgene contains the entire human MCL1 gene, including the endogenous MCL1 promoter. Hemizygous transgenic mice expressed human MCL1 in bone marrow, lymph node, thymus, and spleen (both B- and T-cell populations). Low levels of transgene expression were found in the kidney, small intestine, uterus, lung and liver. |
Mutations Made By | Ruth Craig, Dartmouth Medical School |
This transgenic strain was created on a B6;SJLF1 background. Founder animals were bred to normal C57BL/6J mice to produce hemizygotes. These mice are maintained by mating hemizygotes. Female homozygotes are fertile and do not mate.
When using the B6;SJL-Tg(MCL1)8Caig/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #004187 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(MCL1)8Caig |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.